August 28, 2025

Does Changing Biologics Clear Skin Faster?

The psoriasis treatment ladder may not apply to interclass biologic switching.

Conexiant

August 28, 2025

Girl With Waterdrop-Like Papules: What’s Your Diagnosis?

A teenager with atopic dermatitis presented with several painless, flesh-colored papules limited to the trunk. Dermoscopy and biopsy show selective loss of elastic fibers after prior molluscum contagiosum. What’s your diagnosis?

Conexiant

August 27, 2025

Medical Oddities: Is Smoking Good for the Gut?

From ulcerative colitis’ smoky paradox to protein power, boba belly, hair-friendly diets, and sibling rivalries.

Conexiant

August 26, 2025

Are Daily Drinks Causing Hair Loss?

Comprehensive analysis reveals specific dietary interventions that significantly impact hair health, with some beverages showing harmful effects.

Conexiant

August 25, 2025

Baricitinib Aids Eyebrow, Eyelash Regrowth in Alopecia Areata

This study highlights baricitinib’s effectiveness in promoting eyebrow and eyelash regrowth in patients with alopecia areata across two phase III clinical trials.

Conexiant

August 22, 2025

Nemolizumab Study Tracks 68 Weeks of Relief

A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.

Conexiant

August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 22, 2025

Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings

A recent study found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care.

The ASCO Post

August 22, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post